Receptor scintigraphy with a radioiodinated somatostatin analogue: radiolabeling, purification, biologic activity, and in vivo application in animals
- PMID: 1975618
Receptor scintigraphy with a radioiodinated somatostatin analogue: radiolabeling, purification, biologic activity, and in vivo application in animals
Abstract
Radioiodinated Tyr-3-octreotide, a somatostatin analogue, is a useful ligand for the in vitro detection of somatostatin receptors. In this study, we have investigated the possible in vivo application of this radioligand in the detection of somatostatin receptor-bearing tumors by scintigraphy. The specific somatostatin-like biologic activity of radioiodinated Tyr-3-octreotide was confirmed in vitro: (a) radioiodinated Tyr-3-octreotide competes in the nanomolar range with specific receptor binding of somatostatin to suspended human meningioma membranes and (b) the secretion of growth hormone by cultured rat pituitary cells was similarly inhibited by iodinated Tyr-3-octreotide and somatostatin. In rats, intravenously injected 123I-Tyr-3-octreotide is rapidly cleared from the circulation mainly by the liver. Although this rapid clearance limits the amount of tracer available for somatostatin receptor-bearing tumors, the advantage of this rapid clearance is that the background level is rapidly reduced in favor of scintigraphic imaging of these tumors. Pancreatic tumors in rats were localized by scintigraphy after intravenous injection of 123I-Tyr-3-octreotide.
Similar articles
-
In vivo application of [111In-DTPA-D-Phe1]-octreotide for detection of somatostatin receptor-positive tumors in rats.Life Sci. 1991;49(22):1593-601. doi: 10.1016/0024-3205(91)90053-e. Life Sci. 1991. PMID: 1658516
-
[111In-DTPA-D-Phe1]-octreotide, a potential radiopharmaceutical for imaging of somatostatin receptor-positive tumors: synthesis, radiolabeling and in vitro validation.Life Sci. 1991;49(22):1583-91. doi: 10.1016/0024-3205(91)90052-d. Life Sci. 1991. PMID: 1658515
-
Radioiodinated somatostatin analogue RC-160: preparation, biological activity, in vivo application in rats and comparison with [123I-Tyr3]octreotide.Eur J Nucl Med. 1993 Nov;20(11):1089-94. doi: 10.1007/BF00173488. Eur J Nucl Med. 1993. PMID: 7904561
-
Studies on radiolabeled somatostatin analogues in rats and in patients.Q J Nucl Med. 1996 Sep;40(3):209-20. Q J Nucl Med. 1996. PMID: 8961800 Review.
-
Use of radiolabeled somatostatin analogs in the identification and treatment of somatostatin receptor-bearing tumors.Digestion. 1993;54 Suppl 1:88-91. doi: 10.1159/000201084. Digestion. 1993. PMID: 8359574 Review.
Cited by
-
Octreotide scintigraphy localizes somatostatin receptor-positive islet cell carcinomas.Eur J Nucl Med. 1991;18(11):924-7. doi: 10.1007/BF02258458. Eur J Nucl Med. 1991. PMID: 1684323
-
A new peptide ligand for targeting human carbonic anhydrase IX, identified through the phage display technology.PLoS One. 2010 Dec 31;5(12):e15962. doi: 10.1371/journal.pone.0015962. PLoS One. 2010. PMID: 21209841 Free PMC article.
-
Somatostatin receptor scintigraphy with [111In-DTPA-D-Phe1]- and [123I-Tyr3]-octreotide: the Rotterdam experience with more than 1000 patients.Eur J Nucl Med. 1993 Aug;20(8):716-31. doi: 10.1007/BF00181765. Eur J Nucl Med. 1993. PMID: 8404961 Review.
-
The diagnostic utility of somatostatin receptor scintigraphy in oncology.J Cancer Res Clin Oncol. 1996;122(9):513-32. doi: 10.1007/BF01213548. J Cancer Res Clin Oncol. 1996. PMID: 8781566 Free PMC article. Review.
-
Somatostatin analog sandostatin and inhibition of tumor growth in patients with metastatic endocrine gastroenteropancreatic tumors.World J Surg. 1993 Jul-Aug;17(4):511-9. doi: 10.1007/BF01655111. World J Surg. 1993. PMID: 8395752
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources